Prof. Dr. Helmut Schühlen

1986 - 1998
Facharztausbildung an Universitätskliniken in München, Freiburg und Los Angeles

1999
Habilitation

2005
Ernennung zum außerplanmäßigen Professor durch die Medizinische Fakultät der Technischen Universität München

1999 - 2006
Oberarzt am Deutschen Herzzentrum München

2006 - 2020
Chefarzt der Klinik für Innere Medizin - Kardiologie, Diabetologie und konservative Intensivmedizin am Vivantes Auguste-Viktoria-Klinikum

seit 2021
Direktor Klinische Forschung und Akademische Lehre bei Vivantes

Ausgewählte Originalarbeiten
 

• Eigler NL, Schühlen H, Whiting JS, Pfaff JM, Zeiher AM, Gu S
  Digital angiographic impulse response analysis of regional myocardial perfusion: estimation of coronary flow, flow reserve, and distribution volume by compartmental transit time measurement in a canine model
  Circ Res 1991; 68: 870-880
• Schühlen H, Eigler NL, Whiting JS
  Grading the angiographic extent of collateral filling: Comparison with coronary flow, collateral flow, and regional coronary flow distribution measurements
  Int J Card Imag 1994; 10: 25-33
• Schühlen H, Eigler NL, Whiting JS
  Digital angiographic impulse response analysis of regional myocardial perfusion: Detection of autoregulatory changes in nonstenotic coronary arteries induced by collateral flow to adjacent stenotic arteries
  Circulation 1994; 89: 1004-1012
• Schühlen H, Eigler NL, Zeiher AM, Rombach MM, Whiting JS
  Digital angiographic assessment of the physiologic changes to the regional microcirculation induced by successful coronary angioplasty
  Circulation 1994; 90: 163-171
• Schömig A, Kastrati A, Mudra H, Blasini R, Schühlen H, Klauss V, Richardt G, Neumann FJ
  Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure
  Circulation 1994; 90: 2716-2724
• Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K
  A randomized comparison of antiplatelet and anticoagulation therapy after coronary stent placement
  N Engl J Med 1996; 334: 1084-1089
• Schömig A, Neumann FJ, Walter H, Schühlen H, Hadamitzky M, Zitzmann-Roth EM, Dirschinger J, Hausleiter J, Blasini R, Schmitt C, Alt E, Kastrati A
  Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy
  J Am Coll Cardiol 1997 ;29: 28-34
• Schühlen H, Hadamitzky M, Walter H, Ulm K, Schömig A
  Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement
  Circulation 1997; 95: 2015-2021
• Schühlen H, Kastrati A, Dirschinger J, Hausleiter J, Elezi S, Wehinger A, Pache J, Hadamitzky M, Schömig A
  Intracoronary stenting and risk for major adverse cardiac events during the first month
  Circulation 1998; 98: 104-111
• Schühlen H, Eigler NL, Whiting JS, Haubner R, Hausleiter J, Dirschinger J, Kastrati A, Schwaiger M, Schömig A
  Usefulness of intracoronary brachytherapy for in-stent restenosis with a 188Re-liquid-filled balloon
  Am J Cardiol 2001; 87: 463-466
• Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schühlen H, Neumann FJ, Fleckenstein M, Pfafferoth C, Seyfarth M, Schömig A
  Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial
  Circulation 2001; 103:2816-2821
• Schühlen H, Kastrati A, Pache J, Dirschinger J, Schömig A
  Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement. Analysis of 5678 patients with a four-week ticlopidine regimen
  J Am Coll Cardiol 2001; 37:2066-2073
• Hausleiter J, Kastrati A, Mehilli J, Schühlen H, Pache J, Dirschinger J, Schricke U, Schwaiger M, Markward C, Schömig A
  Impact of acute myocardial infarction location on myocardial salvage after stenting or thrombolysis (results from the STOPAMI 1 and 2 trials): Stent Versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction
  Am J Cardiol 2003; 91: 341-343
• Dibra A, Mehilli J, Schwaiger M, Schühlen H, Bollwein H, Braun S, Neverve J, Schömig A, Kastrati A
  Predictive value of basal C-reactive protein levels for myocardial salvage in patients with acute myocardial infarction is dependent on the type of reperfusion treatment
  Eur Heart J 2003; 24: 1128-1133
• Mehilli J, Kastrati A, Bollwein H, Dibra A, Schühlen H, Dirschinger J, Schömig A
  Gender and restenosis after coronary stenting
  Eur Heart J 2003; 24: 1523-1530
• Schömig A, Ndrepepa G, Mehilli J, Schwaiger M, Schühlen H, Nekolla S, Pache J, Martinoff S, Bollwein H, Kastrati A
  Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis
  Circulation 2003; 108: 1084-1088
• Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg J, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schömig A; for the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment (ISAR-REACT) Study Investigators
  A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel
  N Engl J Med 2004; 350: 232-238
• Schühlen H, Kastrati A, Mehilli J, Hausleiter J, Pache J, Dirschinger J, Schömig A
  Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement
  Am Heart J 2004; 147: 317-322
• Kastrati A, Mehilli J, Nekolla S, Bollwein H, Martinoff S, Pache J, Schühlen H, Seyfarth M, Gawaz M, Neumann FJ, Dirschinger J, Schwaiger M, Schömig A, for the Stent Or PTCA for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Ineligible for Thrombolysis (STOPAMI-3) Study Investigators
  A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy
  J Am Coll Cardiol 2004; 43: 734-741
• Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger P, Schömig A; for the Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators
  A randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel
  Circulation 2004; 110: 3627-3635
• Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schühlen H, Schmitt C, Dirschinger J, Schömig A, for the ISAR-DESIRE Study Investigators
  Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent Restenosis
  JAMA 2005; 293: 165-171
• Schömig A, Mehilli J, Antoniucci D, Ndrepepa G, Markwardt C, Di Pede F, Nekolla SG, Schlotterbeck K, Schühlen H, Pache J, Seyfarth M, Martinoff S, Benzer W, Schmitt C, Dirschinger J, Schwaiger M, Kastrati A, for the Beyond 12 hours Reperfusion AlternatiVe Evaluation (BRAVE-2) Trial Investigators
  Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial
  JAMA 2005; 293: 2865-2872
• Dibra A, Kastrati A, Mehilli J, Pache J, Schühlen H, von Beckerath N, Wessely R, Dirschinger J, Schömig A, for the Intracoronary Stenting and Angiographic Results: Do Diabetic Patients Derive Similar Benefit From Paclitaxel-Eluting and Sirolimus-Eluting Stents? (ISAR-DIABETES) Study Investigators
  Paclitaxel-Eluting Stent Versus Sirolimus-Eluting Stent for the Prevention of Restenosis in Diabetic Patients with Coronary Artery Disease
  N Engl J Med 2005; 353: 553-670
• Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A for the Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators
  Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial
  JAMA 2006; 295: 1531-1538
• Schühlen H, Kastrati A, Mehilli J, Hausleiter J, Dirschinger J, Dotzer F, Bollwein H, Schömig A
  Abciximab And Angiographic Restenosis After Coronary Stent Placement. Analysis of the Angiographic Substudy of ISAR-REACT - A Double-Blind, Placebo-Controlled, Randomized Trial Evaluating Abciximab in Patients Undergoing Elective Percutaneous Coronary Interventions After Pretreatment With a High Loading Dose of Clopidogrel
  Am Heart J 2006; 151: 1248-1254
• Dawkins KD, Verheye S, Schühlen H, Dens J, Mudra H, Rutsch W, Stella P, Di Mario C, Thomas M, Serruys PW, Colombo A.
  The European cobalt STent with Antiproliferative for Restenosis trial (EuroSTAR): 12 month results
  EuroIntervention 2007; 3: 82-88
• Thiele H, Wöhrle J, Neuhaus P, Brosteanu O, Sick P, Prondzinsky R, Birkemeyer R, Wiemer M, Kerber S, Schühlen H, Kleinertz K, Axthelm C, Zimmermann R, Rittger H, Braun-Dullaeus RC, Lauer B, Burckhardt W, Ferrari M, Bergmann MW, Hambrecht R, Schuler G; for the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) Investigators.
  Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial.
  Am Heart J 2010; 159: 547-54
• Maier B, Behrens S, Graf-Bothe C, Kuckuck H, Röhnisch JU, Schöller RG, Schühlen H, Theres HP.
  Time of admission, quality of PCI care, and outcome of patients with ST-elevation myocardial infarction
  Clin Res Cardiol 2010; 99: 565–572
• Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, Laugwitz KL, Pache J, Ott I, Hausleiter J, Seyfarth M, Gick M, Antoniucci D, Schömig A, Berger PB, Mehilli J; ISAR-REACT 4 Trial Investigators.
  Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
  N Engl J Med. 2011; 365: 1980-9.
• Ebbinghaus J, Maier B, Schoeller R, Schühlen H, Theres H, Behrens S.
  Routine early invasive strategy and in-hospital mortality in women with non-ST-elevation myocardial infarction: results from the Berlin Myocardial Infarction Registry (BMIR).
  Int J Cardiol 2012; 158: 78-82
• Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Böhm M, Ebelt H, Schneider S, Schuler G, Werdan K; IABP-SHOCK II Trial Investigators.
  Intraaortic balloon support for myocardial infarction with cardiogenic shock.
  N Engl J Med. 2012; 367: 1287-96.
• Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, de Waha A, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Lauer B, Böhm M, Ebelt H, Schneider S, Werdan K, Schuler G; Intraaortic Balloon Pump in cardiogenic shock II (IABP-SHOCK II) trial investigators.
  Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial.
  Lancet 2013; 382: 1638-45.
• Schühlen H.
  Pre-specified versus post-hoc subgroup analyses. Are we wiser before or after a trial has been performed ? [editorial]
  Eur Heart J 2014; 35: 2055-2057
• Zeymer U, Hochadel M, Andresen D, Schühlen H, Brachmann J, Elsässer A, Gitt A, Zahn R.
  Immediate multivessel percutaneous coonary intervention versus culprid lesion intervention in patients with acute myocardial infartion complicated by cardiogenic shock: results of the ALKK-PCI registry.
  Eurointervention 2015; 11: 280-5.
• Stockburger M, Maier B, Fröhlich G, Rutsch W, Behrens S, Schoeller R, Theres H, Poloczek S, Plock G, Schühlen H. The Emergency Medical Care of Patients With Acute Myocardial Infarction.
  Dtsch Arztebl Int. 2016; 113: 497-502.
• Maier B, Wagner K, Behrens S, Bruch L, Busse R, Schmidt D, Schühlen H, Thieme R, Theres H.
  Comparing routine administrative data with registry data for assessing quality of hospital care in patients with myocardial infarction using deterministic record linkage.
  BMC Health Serv Res 2016; 16: 605.
• Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flügel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Möllmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schühlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tölg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A; ISAR-REACT 5 Trial Investigators.
  Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
  N Engl J Med 2019; 381: 1524-1534.
• Dreger H, Bruch L, Maier B, Schühlen H.
  Stationäre Aufnahmen von Patienten mit akutem Myokardinfarkt während der COVID-19-Pandemie in Berlin.
  Dtsch Arztebl Int 2020; 117:597-598
• Riehle L, Maier B, Behrens S, Bruch L, Schoeller R,Schühlen H, Stockburger M, Theres H, Leistner DM, Landmesser U, Fröhlich GM.
  Changes in treatment for NSTEMI in women and the elderly over the past 16 years in a large real-world population
  Int J Cardiol 2020; 316:7-12
• Maier B, Loewe A, Larscheid P, Behrens S, Bruch L, Busse R, Schaefer H, Schoeller R,Schühlen H, Theres H, Stockburger M.
  Out-of-Hospital and in-Hospital Death from Myocardial Infarction in Berlin.
  Gesundheitswesen 2021; 83:291-296

Dissertation

Vergleich einer niedrigen mit einer mittleren Dosierung von Beta-Acetyl-Digoxin bei der Behandlung der Herzinsuffizienz
Medizinische Fakultät der Ludwig-Maximilians-Universität, München, 1985

Habilitationsschrift

Risiko schwerwiegender kardialer Komplikationen innerhalb des ersten Monats nach koronarer Stentimplantation
Medizinische Fakultät der Technischen Universität München, 1998

Buchbeiträge

• Meister W, Schühlen H, Scheininger M, Theisen K
  Low versus medium dosage digoxin therapy in patients with heart failure. A randomized, double-blind, cross-over study
  In: Cardiac Glycosides 1785 - 1985. Erdmann E, Greeff K, Skou JC (eds.)
  Steinkopff Verlag, Darmstadt, 1986, S. 519-525
• Höffler D, Schühlen H
  Lexikalisches Kompendium der Medizin: Koronare Herzerkrankung
  Aesopus Verlag, Zug, 1988
• Whiting JS, Eigler NL, Schühlen H, Pfaff JM
  Myocardial perfusion estimation by contrast dilution imaging
  In: Imaging, Measurements and Analysis of the Heart. Sideman S, Beyar R (eds.)
  Hemisphere Publishing, New York, 1991, S. 227-239
• Schühlen H, Schömig A
  Impact of strut thickness and stent design on early and late outcomes of coronary stenting
  In: Textbook of Coronary Stenting. Stone GW, Leon MB (eds.)
  in press

• Deutsche Gesellschaft für Kardiologie
• European Society of Cardiology (Fellow, FESC)
• American College of Cardiology (Fellow, FACC)
• American Heart Association
• Berlin-Brandenburger Herzinfarktregister (Vorstandsmitglied)